Epithelial ovarian cancer (EOC) represents the leading Background: cause of death from gynecologic malignancies worldwide. In Sudan, ovarian cancer represents the fourth most frequent tumors among females. somatic mutations is a defining feature of ovarian high-grade serous TP53 carcinoma. However, sequencing is not feasible in most low-and p53 middle-income countries, like Sudan, and its frequency varies greatly. The study aimed to determine the frequency of p53 overexpression and its relationship with tumor types I and II and tumor grade among Sudanese women with EOC.
serous, but negative in low-grade serous tumors. Our result showed a significant association between p53 over-expression and tumor type and grade, and can help discriminate between high-and low-grade serous carcinomas.
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Immunohistochemical staining for p53 was considered as an essential biomarker for clinical trials targeting mutant p53 and used in the diagnostic workup of carcinomas of multiple sites, including ovarian cancers 16 . It is used as a substitute for TP53 mutational analysis, these mutations were global in high-grade serous ovarian cancer (HGSOC) (over 96% were mutated), so were used to discriminates between high-and lowgrade serous carcinomas [17] [18] [19] [20] . Access to TP53 sequencing is not feasible in many low-and middle-income countries; pathologists there used p53 immunohistochemistry, which is quick, easy to perform, inexpensive and can approach 100% specificity for the presence of TP53 mutation. Its high negative predictive value is clinically useful as it can exclude the possibility of a low-grade serous tumor [18] [19] [20] . To our knowledge, there are no published reports about the frequency of p53 immunostaining in type I and II EOC in Sudan. The study aimed to determine the frequency of p53 overexpression and its relationship with tumor types I and II and tumor grades among Sudanese women with EOC.
Methods

Study background
A cross-sectional, hospital-based study was implemented. All 114 available formalin-fixed paraffin-embedded tissue blocks (convenience sampling) previously diagnosed as epithelial ovarian cancer were collected during the period 2013-2016, in six governmental hospitals in Khartoum state, Sudan (The National Public Health Laboratory, Maternity Hospital, Military Omdurman Hospital, Alribat, Bahri, and Omdurman Teaching Hospital). Well-preserved tissue blocks with adequate tissue left for tissue microarray (TMA) procedure were included. Inadequate tissue blocks, and cases with missing tissue blocks were excluded. Slides from the original paraffin blocks were stained with hematoxylin and eosin (H&E), were reviewed according to 2014 WHO classification of ovarian tumors 21 , and were graded and typed according to the Kurman model 8 .
Construction of a microarray
Available paraffin-embedded blocks from tumors were used for the construction of a tissue microarray (TMA). Representative areas of the tumor were identified and TMA blocks were constructed using two cores from each case. Sections were obtained from each TMA and were placed on negatively charged slides for immunohistochemistry.
Immunohistochemistry
Immunohistochemistry was performed to measure the protein expression of p53 monoclonal antibodies in ovarian carcinoma cases, as follow: Sections were cut into widths of 3-4 µm and placed on clean, electrostatically charged glass slides. Sections were dried by placing on a hot plate at 60°C for 15 minutes. Sections were dewaxed in two changes of xylene for two minutes. Sections were then hydrated through an ethanol series (100%, 90%, 70%, 50%) and water two minutes for each. Slides were retrieved using the water bath heat-retrieval technique 22 and then treated with 3% hydrogen peroxide for 10 minutes. After that, sections were washed in phosphate buffer saline (PBS) (pH 7.4) for five minutes and treated with a 10% casein solution for 10 minutes. Sections were treated with ready-to-use primary antibody of mouse monoclonal antibody to p53 protein (clone DO7 IgG2b; catalog no AM239-5M; BioGenex, CA) for 30 minutes at room temperature in a humidity chamber, then rinsed in PBS before being treated with Super Sensitive polymer -HRP IHC Detection System (catalog no QD420-YIKE; BioGenex, CA) by incubated with enhancer reagents 15 min at room temperature, followed by a polymer-HRP reagent conjugated to anti-mouse and anti-rabbit secondary antibody for 15 minutes at room temperature, and rinsed in PBS. The entire antibody-enzyme complex is then made visible by incubation with a chromogenic substrate 3,3 diaminobenzidine for 7 minutes then washed in PBS for five minutes. For the staining step, sections were counter-stained in Mayer's hematoxylin for one minute washed and blued in running tap water before they were dehydrated through ascending concentrations of ethanol (50%, 70%, 90%, 100%). Sections were finally cleared in xylene and mounted using DPX. A known p53-positive breast cancer tumor was used as positive control. As the negative control, tumor specimens were immunostained under the same conditions without the primary antibody. Both the quantity of nuclear positivity and the staining intensity were measured in the immune slides examined under a light microscope (Olympus BX41, Japan). The intensity of staining was reported as negative, weak, moderate, or strong (0, 1+,2+,3+) in comparison with the positive controls (internal or external) and it indicated the average staining intensity of the tumor nuclei on the entire slide. An IHC score of p53 staining intensity was categorized as 0 for none, (no brownish color seen using x40 magnification), +1 for weak (brownish color seen using x20 and x40), +2 for moderate (brownish color seen using x10 magnification) and +3 for strong staining (brown color visible using x4 magnification).
The percentage of positive tumor cells was quantified by counting cells manually in at least 100 cells in 10 high power fields, averaged and categorized as ≥75% of cells considered as high overexpression, ≤75-50% considered as moderate expression and less than 50% considered as focal expression. Only 75-100% positive tumor cells with moderate and strong staining intensity considered as positive results.
Statistical analysis
The data were analyzed using the statistical package for social sciences (SPSS version 24) to describe the variables. Pearson's Chi-square test was used to determine a statistically significant association between p53 expression and clinicopathological variables.
Ethical consideration
The study was approved by the ethical committees of Alzaiem Alazhari University and the Ministry of Health, Sudan. Informed consent from patients was waived by the committees, since patients' identity was anonymized, and only laboratory numbers were used. 23 .
Results
Grading and typing of samples
Overexpression of p53
Positive p53 immunostaining was seen in 35.1% (40/114) of ovarian epithelial carcinoma. From the 40 positive cases, staining intensity was as follows: 25 cases exhibited strong staining (+3), and 15 cases were moderate staining (+2). While the remaining 74 cases were considered as negative results (complete absence of p53 expression seen in 45 cases and +1 staining in 29 cases) ( Figure 1-Figure 4 ).
Overexpression of p53 was associated significantly with the histological subtype (p = 0.004) as seen in Table 1 . p53 expression was significantly associated with tumor grade (p = 0.003): it was positive in 49.2% (30/61) of high-grade tumors, 16.7% (1/6) of the non-graded borderline tumors, and 19.15% (9/47) of the low-grade tumors. The association between p53immunohistochemical expression and epithelial ovarian cancer type showed a highly significant association (p = 0.000). p53 was positive in 53.7% (29/54) of Type II and 18.5% (10/54) of Type I tumors ( Table 2 ).
Discussion
Immunohistochemical staining for p53 was used as a surrogate for TP53 mutational analysis to discriminate between high (over 96% was mutated) and low-grade serous carcinomas [17] [18] [19] [20] . The results of some of these studies may be conflicting primarily because of the indiscriminate grouping of TP53 mutations, which can result in either loss of function or gain of function 36 . GOF mutations can convert p53 protein from a tumor suppressor to an oncogene, leading to expression of a mutant p53 protein at a high level, while LOF mutants leading to loss of p53 protein expression 37 . TP53 mutations are classified according to their function as oncomorphic, loss of function and unclassified. Around 21% of all ovarian cancer patients harbor oncomorphic TP53 mutations, which had the highest p53 protein levels and contribute to chemoresistance and cancer progression, and the tumors with unclassified TP53 mutations express the mutated p53 protein at a fairly high level 33 . The differences found between the studies in the frequency of p53 expression may be due to the differences in scoring of p53 expression and interpretation of results: some studies scored this as overexpression (OE), complete absence (CA), cytoplasmic (CY) or normal/wild type (WT) 18, 20 . Some authors consider complete absence of p53 expression as a mutant also because not all TP53 mutations alter the expression of the protein 15, 17, 25 . Complete absence of p53 expression does not indicate TP53 mutation, as a lack of immunoexpression may be found in normal cells 16 . So, we believe that true overexpression (more than 75% of the cells stained positive) was the most important type of mutation to consider due to their importance in clinical practice, as they are chemoresistant mutations 33 and could also be interpreted easily in the immune-slide without any confusion.
Study limitations
The limitations of our study were related to the relatively small sample size. Many cases were found in the lab records but lacking tissue blocks, and some blocks contain less amount of tissue for TMA.
Conclusion
Our study showed that the overexpression of p53 tumor marker is associated with EOC, histological subtype and tumor grade, and found that high-grade serous tumors had a higher percentage of p53 expression in more than 50% of cases, while low grade serous was negative in 100% of the cases. We recommended the use of p53 immunohistochemical staining in the pathologic workup of ovarian carcinomas. Careful attention to laboratory protocols and practical works, including adequate controls, and training in interpretation is needed to make this a reliable test informing diagnosis and subsequent management of ovarian carcinoma. This project contains the following underlying data:
Data availability
• p53 analysis in ovarian cancer (spreadsheet containing details of analysis for each patient sample).
• Uncropped, unprocessed images taken during this study.
Data are available under the terms of the Creative Commons Zero "No rights reserved" data waiver (CC0 1.0 Public domain dedication).
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